5. Evaluate the efficacy, safety, & tolerability of lurasidone in patients with schizophrenia as assessed by the change from baseline to week 8 & to end of cognitive remediation phase in the PANSS total score, Side Effect Checklist, AIMS, SAS, BAS, & frequency of abnormal laboratory values.